175 related articles for article (PubMed ID: 38738384)
1. Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials.
Yang XH; Zhang BL; Cheng Y; Fu SK; Jin HM
Ann Med; 2024 Dec; 56(1):2332956. PubMed ID: 38738384
[TBL] [Abstract][Full Text] [Related]
2. Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials.
Chewcharat A; Chen Y; Thongprayoon C; Harrison AM; Mao MA; Cheungpasitporn W
Intern Med J; 2021 May; 51(5):752-762. PubMed ID: 32149437
[TBL] [Abstract][Full Text] [Related]
3. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
4. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
[TBL] [Abstract][Full Text] [Related]
6. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
[TBL] [Abstract][Full Text] [Related]
8. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China.
Yang H; Li R; Li Q; Yan T; Li Y; Huang Q; Uchida S; Chang W
Int Urol Nephrol; 2023 May; 55(5):1343-1352. PubMed ID: 36534221
[TBL] [Abstract][Full Text] [Related]
9. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
Trials; 2014 Jan; 15():26. PubMed ID: 24433285
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials.
Xie H; Hu N; Pan T; Wu JC; Yu M; Wang DC
BMC Pharmacol Toxicol; 2023 Dec; 24(1):79. PubMed ID: 38098046
[TBL] [Abstract][Full Text] [Related]
11. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article.
Zeng XX; Tang Y; Hu K; Zhou X; Wang J; Zhu L; Liu J; Xu J
Medicine (Baltimore); 2018 Mar; 97(13):e0161. PubMed ID: 29595642
[TBL] [Abstract][Full Text] [Related]
13. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
[TBL] [Abstract][Full Text] [Related]
14. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
[TBL] [Abstract][Full Text] [Related]
15. Febuxostat for treating chronic gout.
Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
[TBL] [Abstract][Full Text] [Related]
16. Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
Kohagura K; Satoh A; Kochi M; Nakamura T; Zamami R; Tana T; Kinjyo K; Funakoshi R; Yamazato M; Ishida A; Sakima A; Iseki K; Arima H; Ohya Y
J Hypertens; 2023 Sep; 41(9):1420-1428. PubMed ID: 37334544
[TBL] [Abstract][Full Text] [Related]
17. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
18. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies.
Jeong HJ; Park WY; Kim SH; Dalbeth N; Son CN
Semin Arthritis Rheum; 2022 Oct; 56():152073. PubMed ID: 35914389
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Kohagura K; Kojima S; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Sugawara M; Mori H; Tsujita K; Matsui K; Hisatome I; Ohya Y; Kimura K; Saito Y; Ogawa H;
Hypertens Res; 2023 Jun; 46(6):1417-1422. PubMed ID: 36750608
[TBL] [Abstract][Full Text] [Related]
20. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
